Clinical Trial Update: CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a biomarker-driven cetuximab-based treatment regimen for metastatic colorectal cancer, currently listed as active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: University of Campania Luigi Vanvitelli | Conditions: Metastatic Colorectal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING